Prescribers and pharmacists are no longer expected to comply with the REMS for Tryvio. The Food and Drug Administration (FDA) has removed the risk evaluation and mitigation strategies (REMS) program ...
The following products no longer have a REMS requirement: Abecma; Breyanzi; Carvykti; Kymriah; Tecartus; and Yescarta. The Food and Drug Administration (FDA) has removed the Risk Evaluation and ...
The FDA has eliminated Risk Evaluation and Mitigation Strategies for all currently approved BCMA- and CD19-directed autologous CAR-T cell immunotherapies, determining that the safety program is no ...
The FDA has officially eliminated clozapine's risk evaluation and mitigation strategy (REMS) program, with all REMS operations stopped as of June 13. The announcement comes several months after a ...
The U.S. Food and Drug Administration (FDA) announced on Friday that it has eliminated the Risk Evaluation and Mitigation Strategies (REMS) for currently approved BCMA- and CD19-directed autologous ...
The FDA no longer expects prescribers, pharmacies, and patients to participate in the risk evaluation and mitigation strategy (REMS) program for the antipsychotic clozapine, the agency announced this ...
Although clinicians and advocates applauded the US Food and Drug Administration (FDA)’s recent decision to discontinue a risk management and evaluation program for the antipsychotic clozapine, some ...
It was only about a year ago that the biopharma industry hailed a decision by the Supreme Court to preserve access to mifepristone, a drug most commonly known for its paired use with another medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results